Pittcon 2027 is a leading conference and expo for laboratory science professionals, featuring cutting-edge technology and educational opportunities. It attracts chemists, scientists, and technologists from various industries.
Pittcon 2027 offers a comprehensive platform for professionals in the field of laboratory science to exchange knowledge and explore the latest advancements in analytical chemistry. Attendees can expect a blend of technical sessions, industry presentations, and an interactive expo featuring products and technologies that are pushing the boundaries of laboratory sciences. This event is essential for those looking to stay ahead in the rapidly evolving landscape of lab technologies.
What you will learn
Latest trends in analytical instrumentation.
Networking opportunities with industry experts.
Hands-on sessions for new lab techniques.
Updates on regulatory compliance.
Discovering innovations in lab technology.
Want to exhibit at this event?
MarketScale can act as a third-party concierge, helping you request exhibitor packages, pricing, and booth availability. No cold calls, no commitment.
Key Highlights
• Keynote sessions by renowned scientists.
• Workshops on laboratory management.
• Exhibitor showcases of new product launches.
• Special sessions on sustainable practices in labs.
Frequently asked questions
Topics & tracks
MarketScale platform
Exhibiting at this event?
Capture customer testimonials onsite, with your iPhone.
Record quick customer interviews at your booth or in the aisle. MarketScale turns each one into a produced video, written article, and social clips.
Learn how →sciences articles
Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade
More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.
Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic
Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.
Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic
Quotient Sciences has initiated a Phase I study of an AI-designed oral formulation, cleared by the MHRA—marking a concrete shift from AI experimentation to clin
MarketScale
MarketScale helps B2B teams cover events like this and turn them into content their market reads. Want to talk through what that looks like?